Aberrant activation of epigenetic BRD9-DGAT1 axis promotes lipid droplets deposition and ferroptosis resistance in YAP-high prostate cancer

Hussain M, Fizazi K, Shore ND, Heidegger I, Smith MR, Tombal B, et al. Metastatic hormone-sensitive prostate cancer and combination treatment outcomes: a review. JAMA Oncol. 2024;10:807–20.

Google Scholar 

Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. part i: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2024;86:148–63.

Google Scholar 

Cheng Q, Butler W, Zhou Y, Zhang H, Tang L, Perkinson K, et al. Pre-existing castration-resistant prostate cancer-like cells in primary prostate cancer promote resistance to hormonal therapy. Eur Urol. 2022;81:446–55.

Google Scholar 

Narayan V, Barber-Rotenberg JS, Jung IY, Lacey SF, Rech AJ, Davis MM, et al. PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat Med. 2022;28:724–34.

Google Scholar 

Hawley JE, Obradovic AZ, Dallos MC, Lim EA, Runcie K, Ager CR, et al. Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer. Cancer Cell. 2023;41:1972–.e1975.

Google Scholar 

Rastogi I, Muralidhar A, McNeel DG. Vaccines as treatments for prostate cancer. Nat Rev Urol. 2023;20:544–59.

Google Scholar 

Chen L, Xu YX, Wang YS, Ren YY, Dong XM, Wu P, et al. Prostate cancer microenvironment: multidimensional regulation of immune cells, vascular system, stromal cells, and microbiota. Mol Cancer. 2024;23:229.

Google Scholar 

Miranda Furtado CL, Dos Santos Luciano MC, Silva Santos RD, Furtado GP, Moraes MO, Pessoa C. Epidrugs: targeting epigenetic marks in cancer treatment. Epigenetics. 2019;14:1164–76.

Google Scholar 

Wilson BG, Roberts CW. SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer. 2011;11:481–92.

Google Scholar 

Malone HA, Roberts CWM. Chromatin remodellers as therapeutic targets. Nat Rev Drug Discov. 2024;23:661–81.

Google Scholar 

Zhuang K, Wang L, Lu C, Liu Z, Yang D, Zhong H, et al. Assessment of SWI/SNF chromatin remodeling complex related genes as potential biomarkers and therapeutic targets in pan-cancer. Mol Cancer. 2024;23:176.

Google Scholar 

Xiao L, Parolia A, Qiao Y, Bawa P, Eyunni S, Mannan R, et al. Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer. Nature. 2022;601:434–9.

Google Scholar 

Gokbayrak B, Altintas UB, Lingadahalli S, Morova T, Huang CF, Ersoy Fazlioglu B, et al. Identification of selective SWI/SNF dependencies in enzalutamide-resistant prostate cancer. Commun Biol. 2025;8:169.

Google Scholar 

Thienger P, Paassen I, Yao X, Rubin PD, Lehner M, Lillis N, et al. A Double-Negative Prostate Cancer Subtype Is Vulnerable to SWI/SNF-Targeting Degrader Molecules. Cancer Res. 2026;86:1570–85.

Google Scholar 

Lv Y, Mo X, Zhang R, Peng Y, Feng T, Zhang Y, et al. Prostate cancer exploits BRD9-driven metabolic reprogramming to shape the aggressive phenotype. Cell Death Dis. 2025;16:326.

Google Scholar 

Barma N, Stone TC, Carmona Echeverria LM, Heavey S. Exploring the value of BRD9 as a biomarker, therapeutic target and co-target in prostate cancer. Biomolecules. 2021;11:1794.

Google Scholar 

Alpsoy A, Utturkar SM, Carter BC, Dhiman A, Torregrosa-Allen SE, Currie MP, et al. BRD9 is a critical regulator of androgen receptor signaling and prostate cancer progression. Cancer Res. 2021;81:820–33.

Google Scholar 

Koundouros N, Poulogiannis G. Reprogramming of fatty acid metabolism in cancer. Br J Cancer. 2020;122:4–22.

Google Scholar 

Mathiowetz AJ, Olzmann JA. Lipid droplets and cellular lipid flux. Nat Cell Biol. 2024;26:331–45.

Google Scholar 

Mondal S, Ghosh S. Liposome-mediated anti-viral drug delivery across blood-brain barrier: Can lipid droplet target be game changers?. Cell Mol Neurobiol. 2023;44:9.

Google Scholar 

Meng Y, Guo D, Lin L, Zhao H, Xu W, Luo S, et al. Glycolytic enzyme PFKL governs lipolysis by promoting lipid droplet-mitochondria tethering to enhance β-oxidation and tumor cell proliferation. Nat Metab. 2024;6:1092–107.

Google Scholar 

Xiao H, Qu Y, Li H, Zhang Y, Fei M, Liang C, et al. HIF-2α/LINC02609/APOL1-mediated lipid storage promotes endoplasmic reticulum homeostasis and regulates tumor progression in clear-cell renal cell carcinoma. J Exp Clin Cancer Res. 2024;43:29.

Google Scholar 

Zhou L, Song Z, Hu J, Liu L, Hou Y, Zhang X, et al. ACSS3 represses prostate cancer progression through downregulating lipid droplet-associated protein PLIN3. Theranostics. 2021;11:841–60.

Google Scholar 

Chauhan SS, Casillas AL, Vizzerra AD, Liou H, Clements AN, Flores CE, et al. PIM1 drives lipid droplet accumulation to promote proliferation and survival in prostate cancer. Oncogene. 2024;43:406–19.

Google Scholar 

Wang Z, Chao Z, Wang Q, Zou F, Song T, Xu L, et al. EXO1/P53/SREBP1 axis-regulated lipid metabolism promotes prostate cancer progression. J Transl Med. 2024;22:104.

Google Scholar 

Yi J, Zhu J, Wu J, Thompson CB, Jiang X. Oncogenic activation of PI3K-AKT-mTOR signaling suppresses ferroptosis via SREBP-mediated lipogenesis. Proc Natl Acad Sci USA. 2020;117:31189–97.

Google Scholar 

Centore RC, Sandoval GJ, Soares LMM, Kadoch C, Chan HM. Mammalian SWI/SNF chromatin remodeling complexes: emerging mechanisms and therapeutic strategies. Trends Genet. 2020;36:936–50.

Google Scholar 

Feng Y, Cai L, Pook M, Liu F, Chang CH, Mouti MA, et al. BRD9-SMAD2/3 orchestrates stemness and tumorigenesis in pancreatic ductal adenocarcinoma. Gastroenterology. 2024;166:139–54.

Google Scholar 

Nguyen TB, Louie SM, Daniele JR, Tran Q, Dillin A, Zoncu R, et al. DGAT1-dependent lipid droplet biogenesis protects mitochondrial function during starvation-induced autophagy. Dev Cell. 2017;42:9–21.e25.

Google Scholar 

Martin LJ, Koegl M, Bader G, Cockcroft XL, Fedorov O, Fiegen D, et al. Structure-based design of an in vivo active selective BRD9 inhibitor. J Med Chem. 2016;59:4462–75.

Google Scholar 

Pan Q, Zhong S, Wang H, Wang X, Li N, Li Y, et al. The ZMYND8-regulated mevalonate pathway endows YAP-high intestinal cancer with metabolic vulnerability. Mol Cell. 2021;81:2736–.e2738.

Google Scholar 

Valdés-Mora F, Clark SJ. Prostate cancer epigenetic biomarkers: next-generation technologies. Oncogene. 2015;34:1609–18.

Google Scholar 

Macedo-Silva C, Benedetti R, Ciardiello F, Cappabianca S, Jerónimo C, Altucci L. Epigenetic mechanisms underlying prostate cancer radioresistance. Clin Epigenetics. 2021;13:125.

Google Scholar 

Li J, Xu C, Lee HJ, Ren S, Zi X, Zhang Z, et al. A genomic and epigenomic atlas of prostate cancer in Asian populations. Nature. 2020;580:93–99.

Google Scholar 

Inoue D, Chew GL, Liu B, Michel BC, Pangallo J, D’Avino AR, et al. Spliceosomal disruption of the non-canonical BAF complex in cancer. Nature. 2019;574:432–6.

Google Scholar 

Wang X, Song C, Ye Y, Gu Y, Li X, Chen P, et al. BRD9-mediated control of the TGF-β/Activin/Nodal pathway regulates self-renewal and differentiation of human embryonic stem cells and progression of cancer cells. Nucleic Acids Res. 2023;51:11634–51.

Google Scholar 

Cui H, Wang Y, Zhou T, Qu L, Zhang X, Wang Y, et al. Targeting DGAT1 inhibits prostate cancer cells growth by inducing autophagy flux blockage via oxidative stress. Oncogene. 2024;43:136–50.

Google Scholar 

Cheng X, Geng F, Pan M, Wu X, Zhong Y, Wang C, et al. Targeting DGAT1 ameliorates glioblastoma by increasing fat catabolism and oxidative stress. Cell Metab. 2020;32:229–242.e228.

Google Scholar 

Zhou J, Simon JM, Liao C, Zhang C, Hu L, Zurlo G, et al. An oncogenic JMJD6-DGAT1 axis tunes the epigenetic regulation of lipid droplet formation in clear cell renal cell carcinoma. Mol Cell. 2022;82:3030–3044.e3038.

Google Scholar 

Remillard D, Savage NA, Kedves AT, Paulk J, Chen X, Garcia FJ, et al. Chemoproteomics enabled discovery of selective probes for NuA4 factor BRD8. ACS Chem Biol. 2021;16:2185–92.

Google Scholar 

Nguyen CDK, Yi C. YAP/TAZ signaling and resistance to cancer therapy. Trends Cancer. 2019;5:283–96.

Google Scholar 

Piccolo S, Panciera T, Contessotto P, Cordenonsi M. YAP/TAZ as master regulators in cancer: modulation, function and therapeutic approaches. Nat Cancer. 2023;4:9–26.

Google Scholar 

Wu L, Ou Z, Liu P, Zhao C, Tong S, Wang R, et al. ATXN3 promotes prostate cancer progression by stabilizing YAP. Cell Commun Signal. 2023;21:152.

Google Scholar 

Li X, Zhuo S, Cho YS, Liu Y, Yang Y, Zhu J, et al. YAP antagonizes TEAD-mediated AR signaling and prostate cancer growth. Embo j. 2023;42:e112184.

Google Scholar 

Gu Y, Wu S, Fan J, Meng Z, Gao G, Liu T, et al. CYLD regulates cell ferroptosis through Hippo/YAP signaling in prostate cancer progression. Cell Death Dis. 2024;15:79.

Google Scholar 

Fu X, Wu H, Li C, Deng G, Chen C. YAP1 inhibits RSL3-induced castration-resistant prostate cancer cell ferroptosis by driving glutamine uptake and metabolism to GSH. Mol Cell Biochem. 2024;479:2415–27.

Google Scholar 

Lee H, Horbath A, Kondiparthi L, Meena JK, Lei G, Dasgupta S, et al. Cell cycle arrest induces lipid droplet formation and confers ferroptosis resistance. Nat Commun. 2024;15:79.

Google Scholar 

Zhang C, Ding J, Lim KS, Zhou W, Miao W, Wu S, et al. JMJD6 rewires ATF4-dependent glutathione metabolism to confer ferroptosis resistance in SPOP-mutated prostate cancer. Cancer Res. 2025;85:1496–513.

Google Scholar 

Yang J, Lu X, Hao JL, Li L, Ruan YT, An XN, et al. VSTM2L protects prostate cancer cells against ferroptosis via inhibiting VDAC1 oligomerization and maintaining mitochondria homeostasis. Nat Commun. 2025;16:1160.

Google Scholar